HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yasumasa Nishimura Selected Research

doranidazole

6/2008Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study.
11/2007Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
4/2004Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yasumasa Nishimura Research Topics

Disease

31Neoplasms (Cancer)
11/2021 - 06/2003
19Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2022 - 03/2003
15Esophageal Neoplasms (Esophageal Cancer)
01/2021 - 05/2002
11Lung Neoplasms (Lung Cancer)
12/2022 - 03/2003
7Prostatic Neoplasms (Prostate Cancer)
04/2022 - 12/2013
6Squamous Cell Carcinoma of Head and Neck
01/2022 - 12/2013
6Head and Neck Neoplasms (Head and Neck Cancer)
01/2022 - 06/2003
5Pancreatic Neoplasms (Pancreatic Cancer)
05/2011 - 04/2004
4Pharyngeal Neoplasms
11/2021 - 06/2010
4Neoplasm Metastasis (Metastasis)
10/2021 - 01/2017
4Breast Neoplasms (Breast Cancer)
05/2021 - 10/2008
4Carcinoma (Carcinomatosis)
01/2021 - 10/2010
4Adenocarcinoma
05/2020 - 06/2010
4Small Cell Lung Carcinoma (Small Cell Lung Cancer)
03/2019 - 03/2003
4Biliary Tract Neoplasms (Biliary Tract Cancer)
11/2015 - 04/2013
3Oropharyngeal Neoplasms
10/2021 - 01/2018
3Glioma (Gliomas)
08/2020 - 06/2003
3Hepatocellular Carcinoma (Hepatoma)
11/2019 - 12/2004
3Brain Neoplasms (Brain Tumor)
03/2019 - 03/2003
3Fistula
10/2017 - 05/2002
2Glioblastoma (Glioblastoma Multiforme)
10/2021 - 06/2003
2Esophageal Squamous Cell Carcinoma
01/2021 - 10/2019
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2021 - 05/2020
2Nasopharyngeal Neoplasms (Cancer of the Nasopharynx)
07/2020 - 02/2010
2Uterine Cervical Neoplasms (Cancer of the Cervix)
09/2019 - 07/2019
2Disease Progression
10/2018 - 10/2017
2Deglutition Disorders (Dysphagia)
10/2017 - 12/2003
2Xerostomia
03/2015 - 07/2005
2Lymphatic Metastasis
12/2013 - 06/2010
2Stomach Neoplasms (Stomach Cancer)
04/2013 - 06/2010
1Radiation Pneumonitis
12/2022
1Hypothyroidism
11/2021
1Keratitis
01/2021
1Stomatitis
01/2021
1Paronychia
01/2021
1Melanoma (Melanoma, Malignant)
08/2020
1Mouth Neoplasms (Oral Cancer)
08/2020
1Unilateral Breast Neoplasms
05/2020
1Weight Loss (Weight Reduction)
07/2019
1Unknown Primary Neoplasms
09/2017
1Leukopenia
09/2016
1Jaundice (Icterus)
07/2014
1Gastrointestinal Neoplasms (Gastrointestinal Cancer)
04/2013

Drug/Important Bio-Agent (IBA)

13Cisplatin (Platino)FDA LinkGeneric
01/2022 - 05/2002
4ErbB Receptors (EGF Receptor)IBA
01/2021 - 01/2011
3DNA (Deoxyribonucleic Acid)IBA
12/2013 - 12/2004
3doranidazoleIBA
06/2008 - 04/2004
3Docetaxel (Taxotere)FDA Link
09/2006 - 06/2003
3Fluorouracil (Carac)FDA LinkGeneric
06/2004 - 05/2002
2L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
10/2021 - 03/2019
2nimotuzumabIBA
01/2021 - 01/2011
2Gefitinib (Iressa)FDA Link
01/2019 - 05/2011
2Carboplatin (JM8)FDA LinkGeneric
10/2018 - 05/2012
2Paclitaxel (Taxol)FDA LinkGeneric
10/2018 - 05/2012
2S-1 plus cisplatinIBA
01/2018 - 12/2011
2PlatinumIBA
10/2017 - 03/2015
2SodiumIBA
01/2016 - 05/2004
2Etoposide (VP 16)FDA LinkGeneric
08/2014 - 01/2010
2IodineIBA
05/2005 - 12/2004
2Contrast MediaIBA
05/2005 - 12/2004
1Pharmaceutical PreparationsIBA
11/2021
1pembrolizumabIBA
10/2021
1Temozolomide (Temodar)FDA LinkGeneric
10/2021
1AlbuminsIBA
10/2021
1C-Reactive ProteinIBA
10/2021
1Biomarkers (Surrogate Marker)IBA
10/2021
1Cetuximab (Erbitux)FDA Link
01/2021
1Immunoglobulin G (IgG)IBA
01/2021
1Immune Checkpoint InhibitorsIBA
01/2021
1Epithelial Cell Adhesion MoleculeIBA
01/2021
1Sirolimus (Rapamycin)FDA Link
08/2020
1TOR Serine-Threonine KinasesIBA
08/2020
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
05/2020
1fluoromisonidazoleIBA
01/2018
1Vinorelbine (Navelbine)FDA LinkGeneric
01/2018
1cepharanthineIBA
09/2016
1Oxygen (Dioxygen)IBA
01/2016
1nedaplatinIBA
12/2013
1titanium silicide (TS-1)IBA
04/2013
1Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
10/2012
1Anaplastic Lymphoma KinaseIBA
10/2012
1GemcitabineFDA Link
06/2012

Therapy/Procedure

74Radiotherapy
12/2022 - 03/2003
26Chemoradiotherapy
01/2022 - 05/2002
22Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
12/2022 - 06/2003
20Drug Therapy (Chemotherapy)
06/2022 - 04/2003
7Therapeutics
10/2021 - 06/2010
4Segmental Mastectomy (Lumpectomy)
05/2021 - 10/2008
3Brachytherapy
10/2017 - 08/2005
2Immunotherapy
11/2021 - 01/2021
2Boron Neutron Capture Therapy
08/2020 - 05/2004
2Hysterectomy
09/2019 - 07/2019
2Consolidation Chemotherapy
10/2018 - 05/2012
2Stents
12/2003 - 08/2003
1Neck Dissection (Radical Neck Dissection)
11/2021
1Hepatectomy
11/2019
1Proton Therapy
11/2019
1Aftercare (After-Treatment)
10/2017
1Adjuvant Chemotherapy
06/2012
1Conformal Radiotherapy
05/2012